CClinicalTrials.gg
Status unknownNCT02575352CPCUpdated May 25, 2018

Calcium Phosphate Cement Registry (CPC Registry)

An observational study in Bone Disease, Fracture Bone and Bone Cyst, sponsored by Graftys SA. Status unknown at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-25.

Sponsored by Graftys SA · Observational

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

CPC REGISTRY is a multi-center, international, prospective, open-label, observational study on the use of injectable calcium phosphate cements for the treatment of bone defects in adults. All patients will be treated with any of the two injectable calcium phosphate bone substitutes (GRAFTYS®HBS/GRAFTYS®Quickset or their private labels) according to standard clinical practice and according to the information provided by GRAFTYS manufacturer in respective device Instructions For Use (IFU).

Read the detailed description

The objective of this observational prospective study is to collect safety and performance data relating to the use of injectable Calcium Phosphate Cements "GRAFTYS®HBS/GRAFTYS®Quickset (or their private labels)" in routine clinical practice from various international hospitals. Therefore this observational study will allow to support data about risk management (established at the end of the product development); and to enhance the current clinical evaluation of products with new clinical data (for longer follow-up). The collected data of this observational study will be "non-identifying data". The patient must have signed a Written Consent Form (for data collection) prior to any data being entered into the electronic Case Report Form.

Patients will be followed as per local standard medical practices of the center for two years. Five follow-up visits/phone calls will be collected (at 3 months (+/-14 days), 6 months (+/- 14 days), 9 months (+/-21 days), 12 months (+/- 30 days) and 24 months (+/-60 days)). Each visit/phone call includes the collection of Adverse Events, the measurement of health status (quality of life and functional scores) and the X-ray scoring (if X-ray imaging is available). No additional exams (other than the routine clinical practice) are requested. The surgeons have to follow their usual practices (e.g. X-Rays have to be performed only if they are scheduled in the routine clinical practice).

All Adverse Events will be collected and monitored at each follow-up visit or follow-up phone call. All Serious Adverse Events must be described via a Serious Adverse Event form in e-CRF and all Adverse Device Effects must be described via a "Product Complaint Form" in e-CRF.

Descriptive analyses will be performed in order to describe: nature of adverse events, their distribution and frequency. Moreover, all factors which may appear predictive for the rate of adverse events will be analyzed (age, sex, amount of CPC injected, delivery system used, diabetes history, smoking habits, alcohol consumption, concomitant treatments/diseases...). For all time-dependent events, life-tables will be able to calculate using the Kaplan Meier estimate method, for a period starting on the date of the procedure up to and including the 24-months follow-up visit.

02

Conditions studied

  • Bone Disease
  • Fracture Bone
  • Bone Cyst

Keywords

  • Bone Substitute
  • Calcium Phosphate Cement
  • GRAFTYS
  • GRAFTYS®HBS
  • GRAFTYS®QUICKSET
  • Bone void filler
  • Bone growth
  • Registry
  • Bone defect
  • Revision arthroplasty
  • Arthrodesis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients eligible and planned for bone defect treatment who meet predefined criteria in Instructions For Use (IFU) of GRAFTYS®HBS/ GRAFTYS®Quickset.

Inclusion criteria

  1. Bone skeletal defects that are not intrinsic to the stability of bone structure OR site which can be stabilized
  2. Bone defects from surgery, trauma, tumor or cyst
  3. Age ≥ 18 years
  4. Patient information and signed informed consent form (for data collection)
  5. Affiliation to a Social Security System schema (or similar system)

Exclusion criteria

Exclusion Criteria:

  1. Patients undergoing radiotherapy or chemotherapy
  2. Patients with inflammatory bone disease
  3. Patients with a calcium metabolism anomaly, severe metabolic disease, vascular or neurological diseases, or immunological deficiencies
  4. Bone site which can lead to the product passing into the joint cavities without appropriate controls (visual, arthroscopic, lavage...).
  5. Bone site which can lead to the product passing into the meningeal spaces
  6. Vertebroplasty and kyphoplasty
  7. Site infected or one suspected of being so
  8. A cranio-maxillofacial defect with a surface area larger than 25 cm2
  9. A site exposed to the sinus (lumen) or nasal mucosa
  10. Pregnant women (or likely to be) or breast-feeding women
  11. Inability to understand the consent and objectives of the study
  12. Unable to undergo medical monitoring for geographical, social or psychological reasons
  13. Persons who are deprived of liberty or under guardianship
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. Adverse Device Effect rate

    Rate of Adverse Events related to bone substitutes (registry devices) for the follow-up period of patients.

    Time frame: For 24 months

Secondary outcomes

  1. Technical Success rate

    Technical Success rate defined as successful delivery of the bone substitute in the target defect bone without evidence of delivery device or bone substitute malfunction. (NOTE: Malfunction is definied as a failure of the medical device to perform in accordance with its intended purpose when used in accordance with the Instructions For Uses (IFU)).

    Time frame: At surgical procedure

  2. Device Deficiencies rate

    Device deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. NOTE: Device deficiencies include malfunctions, use errors, and inadequate labelling.

    Time frame: At surgical procedure

  3. Serious Adverse Events rate in the peroperative period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: At surgical procedure

  4. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: 3 months post index procedure

  5. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: 6 months post index procedure

  6. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: 9 months post index procedure

  7. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: 12 months post index procedure

  8. Serious Adverse Events rate during the follow-up period

    Serious Adverse Event is defined as any adverse event that: 1. Led to a death, 2. Led to serious deterioration in health of the subject that either resulted in: 1. a life-threatening illness or injury, or 2. a permanent impairment of a body structure or a body function, or 3. in-patient or prolonged hospitalization, or 4. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function. 3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.

    Time frame: 24 months post index procedure

  9. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Time frame: 3 months post index procedure

  10. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Time frame: 6 months post index procedure

  11. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Time frame: 9 months post index procedure

  12. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Time frame: 12 months post index procedure

  13. Bone reconstruction evolution after surgery (if X-rays are available)

    X-ray scoring systems have been implemented according to the medical literature criteria. For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria. As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant. The maximum score for both groups (trauma/arthrodesis \& cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).

    Time frame: 24 months post index procedure

  14. Quality of life score at baseline (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: At baseline (pre-operative)

  15. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: 3 months post index procedure

  16. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: 6 months post index procedure

  17. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: 9 months post index procedure

  18. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: 12 months post index procedure

  19. Quality of life score evolution after surgery (EQ-5D-3L)

    This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients. EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview. The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.

    Time frame: 24 months post index procedure

  20. Functional score at baseline (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: At baseline (pre-operative)

  21. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: 3 months post index procedure

  22. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: 6 months post index procedure

  23. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: 9 months post index procedure

  24. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: 12 months post index procedure

  25. Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).

    Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect: * Hand/wrist/ elbow/shoulder: Quick-DASH score (Disabilities of Arm, Shoulder \& Hand). * Knee: KOOS-PS (Knee Injury \& Osteoarthritis Outcome Score- Physical function Short form) * Hip: HOOS-PS (Hip disability and Osteoarthritis Outcome Score- Physical function Short form) * Foot/Ankle: Kitaoka \& al's criteria, AOFAS Ankle-Hindfoot Scale; Forefoot Scale; Midfoot scale.

    Time frame: 24 months post index procedure

  26. Surgeon's Satisfaction survey with registry device

    Surgeon's Satisfaction survey with registry device (about mixing ability, injecting ability and moldability) thanks to a 100-mm Visual Analog Scale (VAS). A score of zero indicated absolutely inacceptable, while a score of 100 indicated very satisfying.

    Time frame: At surgical procedure

06

Study locations

11 of 11 sites recruiting
  • Hôpital La Timone
    Marseille, 13385, France
    • Sébastien PARRATTE, MD, Prof. · Contact
    • Sébastien PARRATTE, MD, Prof. · Principal investigator
    Recruiting
  • Marseille, France
    Recruiting
  • Paris, France
    Recruiting
  • Saint-louis, France
    Recruiting
  • Kiel, Germany
    Recruiting
  • Ratzeburg, Germany
    Recruiting
  • Würzburg, Germany
    Recruiting
  • Palermo, Italy
    Recruiting
  • Piacenza, Italy
    Recruiting
  • Fort-de-France, Martinique
    Recruiting
  • Yverdon-les-bains, Switzerland
    Recruiting
07

Registry details

Key details

Study ID
NCT02575352
Lead sponsor
Graftys SA
Collaborators
Clinfile
Responsible party
Sponsor
First posted
Oct 14, 2015
Start date
May 2015
Primary completion
May 2021 (estimated)
Completion
May 2021 (estimated)
Last update
May 25, 2018

Study contacts

Mehan ALTAIFI
Contact
mehan.altaifi@graftys.fr
+33(0) 442 603 000
Nathalie BAUDRY
Contact
nathalie.baudry@graftys.fr
+33(0) 442 603 009
Sébastien PARRATTE, MD, Prof
principal investigator · Hospital of "LA TIMONE"

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion